3,510 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Purchased by Verus Capital Partners LLC

Verus Capital Partners LLC acquired a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 3,510 shares of the biotechnology company’s stock, valued at approximately $222,000.

Several other institutional investors also recently bought and sold shares of the business. Signaturefd LLC boosted its position in Viking Therapeutics by 16.2% during the 3rd quarter. Signaturefd LLC now owns 1,351 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 188 shares during the period. Keudell Morrison Wealth Management raised its stake in Viking Therapeutics by 5.9% during the third quarter. Keudell Morrison Wealth Management now owns 4,306 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 241 shares during the period. GAMMA Investing LLC increased its stake in shares of Viking Therapeutics by 124.6% in the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 243 shares during the period. Massmutual Trust Co. FSB ADV increased its stake in shares of Viking Therapeutics by 84.3% in the third quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 253 shares during the period. Finally, Los Angeles Capital Management LLC increased its stake in shares of Viking Therapeutics by 3.1% during the second quarter. Los Angeles Capital Management LLC now owns 12,278 shares of the biotechnology company’s stock valued at $651,000 after acquiring an additional 372 shares during the period. 76.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Viking Therapeutics

In related news, Director Lawson Macartney sold 2,000 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $68.67, for a total transaction of $137,340.00. Following the completion of the transaction, the director now owns 47,965 shares in the company, valued at approximately $3,293,756.55. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Sarah Kathryn Rouan sold 11,000 shares of Viking Therapeutics stock in a transaction on Friday, October 25th. The shares were sold at an average price of $80.89, for a total value of $889,790.00. Following the completion of the sale, the director now owns 9,500 shares in the company, valued at $768,455. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Lawson Macartney sold 2,000 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $68.67, for a total transaction of $137,340.00. Following the sale, the director now directly owns 47,965 shares in the company, valued at approximately $3,293,756.55. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 506,687 shares of company stock worth $36,029,679 over the last ninety days. Corporate insiders own 4.70% of the company’s stock.

Viking Therapeutics Stock Performance

Shares of NASDAQ VKTX opened at $55.06 on Thursday. The firm has a market cap of $6.14 billion, a price-to-earnings ratio of -59.20 and a beta of 1.00. Viking Therapeutics, Inc. has a 1 year low of $10.34 and a 1 year high of $99.41. The stock’s 50-day simple moving average is $64.72 and its 200-day simple moving average is $61.66.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, October 23rd. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. During the same quarter last year, the business posted ($0.23) earnings per share. As a group, research analysts predict that Viking Therapeutics, Inc. will post -0.98 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Morgan Stanley reissued an “overweight” rating and issued a $105.00 target price on shares of Viking Therapeutics in a research note on Thursday, September 12th. HC Wainwright increased their price objective on shares of Viking Therapeutics from $90.00 to $102.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a research report on Tuesday, October 15th. JPMorgan Chase & Co. assumed coverage on shares of Viking Therapeutics in a report on Wednesday, September 11th. They issued an “overweight” rating and a $80.00 target price on the stock. Finally, Oppenheimer restated an “outperform” rating and issued a $138.00 price target on shares of Viking Therapeutics in a research report on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $109.80.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.